Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04650581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Study acronym: FINER
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv39
  2. Results first posted: Jan 28, 2026
    • Primary endpoint revised
    • Secondary endpoints: 13 to 2
    v38
  3. Primary completion date changed from estimate of Jun 30, 2025 to May 23, 2025v37
  4. Primary completion date: Dec 31, 2024 to Jun 30, 2025v36
  5. Primary completion date: Jun 30, 2024 to Dec 31, 2024v35
Show 33 earlier versionsHide 33 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 39 of 39 sites
    v34
  2. Re-verified, no change to tracked fieldsv33
  3. Site details revised at 13 of 39 sitesv32
  4. Study sites: 40 to 39v31
  5. Site details revised at 1 of 40 sitesv30
  6. Site contacts updated at 1 of 40 sitesv29
  7. Start date: Dec 1, 2020 to Jan 27, 2021v28
  8. Study sites: 41 to 40v27
  9. Study sites: 40 to 41v26
  10. Site contacts updated at 1 of 40 sitesv25
  11. Site details revised at 2 of 40 sitesv24
  12. Study sites: 39 to 40v23
  13. Study sites: 38 to 39v22
  14. Site details revised at 1 of 38 sitesv21
  15. Study sites: 37 to 38v20
  16. Re-verified, no change to tracked fieldsv19
  17. Study sites: 36 to 37v18
  18. Study sites: 34 to 36v17
  19. Study sites: 27 to 34v16
  20. Study sites: 22 to 27v15
  21. Study sites: 20 to 22v14
  22. Re-verified, no change to tracked fieldsv13
  23. Study sites: 19 to 20v12
  24. Site contacts updated at 1 of 19 sitesv11
  25. Study sites revised (19)v10
  26. Study sites: 14 to 19v9
  27. Site details revised at 1 of 14 sitesv8
  28. Study sites: 12 to 14v7
  29. Site details revised at 3 of 12 sitesv6
  30. Study sites: 7 to 12v5
  31. Study sites: 4 to 7v4
  32. Study sites: 2 to 4v3
  33. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 2020 to Dec 1, 2020
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
Trial Details
NCT Number NCT04650581
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Hoffmann-La Roche
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov